The transcription factor JUN is frequently overexpressed in multiple genetic subtypes of acute myeloid leukemia (AML); however, the functional role of JUN in AML is not well defined. Here we report that short hairpin RNA (shRNA)-mediated inhibition of JUN decreases AML cell survival and propagation in vivo. By performing RNA sequencing analysis, we discovered that JUN inhibition reduces the transcriptional output of the unfolded protein response (UPR), an intracellular signaling transduction network activated by endoplasmic reticulum (ER) stress. Specifically, we found that JUN is activated by MEK signaling in response to ER stress, and that JUN binds to the promoters of several key UPR effectors, such as XBP1 and ATF4, to activate their transcription and allow AML cells to properly negotiate ER stress. In addition, we observed that shRNA-mediated inhibition of XBP1 or ATF4 induces AML cell apoptosis and significantly extends disease latency in vivo tying the reduced survival mediated by JUN inhibition to the loss of prosurvival UPR signaling. These data uncover a previously unrecognized role of JUN as a regulator of the UPR as well as provide key new insights into the how ER stress responses contribute to AML and identify JUN and the UPR as promising therapeutic targets in this disease.
INTRODUCTION
Although numerous genetic mutations and chromosomal aberrations that drive the development of acute myeloid leukemia (AML) have been identified, 1,2 the molecular components that are not mutated, but whose altered expression and function contribute to the etiology and pathophysiology of AML remain largely unknown. The transcription factor JUN is highly expressed and activated in a variety of human cancers, including AML. [3] [4] [5] [6] [7] [8] [9] In comparison with healthy controls, the mean expression of JUN is substantially higher in AML patient samples bearing t(8;21), t (15;17) , inv (16) , 11q23 translocations as well as in those possessing complex or normal karyotype. 5, 6 Elevated JUN expression has also been linked to both AML recurrence and therapy-related myelodysplastic syndrome/AML. 7, 8 However, the functional and molecular roles of JUN in AML cell biology and progression are largely unknown.
The unfolded protein response (UPR) is a signal transduction network comprised of three integrated signaling pathways, PERK, IRE1α and ATF6, that are collectively activated in cells experiencing endoplasmic reticulum (ER) stress. [10] [11] [12] Under conditions of acute or reparable ER stress, PERK, IRE1α and ATF6 coordinate the activation of ER stress correcting transcriptional programs. 12, 13 Specifically, PERK indirectly activates the transcription factor ATF4, which then stimulates the expression of genes that regulate amino-acid import and redox biology to facilitate oxidative protein folding. [13] [14] [15] [16] The endoribonuclease IRE1α drives the processing of XBP1 messenger RNA (mRNA) to generate transcripts (called XBP1s) that code for the transcriptional activator XBP1s. [17] [18] [19] XBP1s and ATF6 engage transcriptional programs that facilitate cellular processes such as protein folding, ER entry of proteins, ER-associated protein degradation and phospholipid biosynthesis. [19] [20] [21] [22] [23] [24] However, when ER stress is chronic or cannot be mitigated, the UPR initiates both transcriptional (for example, induction of CHOP) and non-transcriptional programs to promote cell death. 12, 13, [25] [26] [27] [28] [29] Components of the UPR are mutated or aberrantly expressed in several settings of human cancer. 11, 30, 31 In AML, the mean expression of XBP1 is significantly higher in AML patients compared with normal human CD34+ hematopoietic stem and progenitor cells, and this increased expression is associated with hypomethylation of the XBP1 promoter. 32 Several studies have also observed that markers of activated UPR signaling, such as the presence of the XBP1s splice variant and increased expression of UPR-activated genes GRP78 (encoded by HSPA5), PDI and CALR, are detectable in a significant number of AML patient samples. [33] [34] [35] However, the regulators of the UPR and the functional consequences of altered UPR signaling in AML have not been defined.
In this study, we have discovered that inhibition of JUN leads to widespread AML cell apoptosis and diminishes leukemia cell propagation in a genetically engineered mouse model of AML driven by the human leukemogenic fusion protein MLL-AF9 as well as human AML cell xenografts. At the molecular level, we have found that JUN regulates the transcription of numerous genes targeted by the UPR, including XBP1 and ATF4. Specifically, we have found that JUN binds to the promoters of XBP1 and ATF4, and that inhibition of JUN reduces UPR transcriptional output and cell survival in both unstressed and ER-stressed AML cells. Moreover, retrospective analyses of gene expression profiles of patient-derived AML cells revealed that JUN expression correlates with UPR target gene expression in multiple genetic subtypes of AML. We have also discovered that JUN is activated in response to ER stress by MEK signaling. Last, we have also observed that inhibition of XBP1 or ATF4 leads to widespread AML cell apoptosis and a significant increase in the time of disease onset in vivo. Collectively, these data show that JUN is a key regulator of UPR signaling, and through these effects, JUN has a critical role in facilitating AML cell survival and progression.
MATERIALS AND METHODS

Cell culture
Human and murine AML cell lines were described previously 9 and were cultured in standard culture conditions, and cell line identity and purity were verified using the Multiplex Cell Authentication and Contamination Tests (Multiplexion, Friedrichshafen, Germany).
Lentiviral and retroviral constructs
Human and mouse AML cells were transduced with recombinant lentiviruses or retroviruses as described previously. 9 Construct information is described in Supplementary Material and methods.
RNA-seq analysis
Total RNA was extracted using TRIZOL (ThermoFisher-Life Technologies, Waltham, MA, USA). The sequencing libraries were constructed from 500 ng of total RNA using the Illumina's TruSeq RNA Sample pre kit V2 (Illumina, San Diego, CA, USA) following the manufacturer instructions. The fragment size of RNA sequencing (RNA-seq) libraries was verified using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA, USA), and the concentrations were determined using Qubit instrument (ThermoFisherLife Technologies). The libraries were loaded onto the Illumina HiSeq 2500 at 6-10 pM on the rapid mode for 2 × 100 bp paired-end read sequencing. RNA-seq analysis described in Supplementary Material and methods.
Western blot
Western blot analyses were carried out as previously described, 9 and primary and secondary antibodies are included in Supplementary Material and methods.
RNA analysis
RNA was extracted using the QIAGEN RNAeasy kit (QIAGEN, Hilden, Germany) and converted to complementary DNA (cDNA) using the High Capacity cDNA reverse transcription kit (ThermoFisher-Life Technologies). cDNA was amplified using SYBR Green (ThermoFisher, Waltham, MA, USA) and primers (listed in Supplementary Material and methods) on StepOnePlus.
Chromatin immunoprecipitation assays
Chromatin immunoprecipitation assays was performed in THP-1 cells. Cells were crosslinked with 1% formaldehyde for 15 min and sonicated for 30 s with 30 s interval of rest between sonications for 10 cycles, which yielded DNA fragments of~150-250 bp. The chromatin was precipitated by anti-JUN (Cat#: 9165 S, Lot#: 9) or IgG control (Cat#: 2729 S, Lot#: 7) overnight at 4°C. The eluted DNA was subjected to real-time PCR analysis with primers (listed in Supplementary Material and methods) and SYBR Green (ThermoFisher-Applied Biosystems, Waltham, MA, USA).
Cell growth and survival
To assess cell death and proliferation, cells from each condition were stained with Annexin V and propidium iodide (PI) or anti-BrdU according to the manufacturer's instruction (BD Biosciences, San Jose, CA, USA). To assess cell growth, cells were incubated with CellTiter Aqueous One solution (Promega, Madison, WI, USA) according to the manufacturer's instructions.
Animal studies
All animal studies were conducted under the approval of the Fox Chase Cancer Center IUCAC (Protocol #13-1). Detailed descriptions of mouse studies are described in the Supplementary Material and methods. Figure 1D ). Comparable JUN inhibition-associated defects in cell expansion and survival were also observed in the human AML cells lines Kasumi-1, HL-60, Mono-mac-6, NOMO1, MV4-11, SKM1 and OCI-AML3 ( Supplementary Figures 1E and F ; data not shown). The effects of JUN shRNA treatment on cell growth and viability are very likely to result from on target knockdown of JUN, as shJUN-1 and shJUN-2 had essentially no effect on the human AML cell line ME-1, which express undetectable levels of JUN protein ( Supplementary Figures 1E  and F ; data not shown). Collectively, these data suggest that elevated JUN expression supports AML cell proliferation and survival.
RESULTS
JUN is
JUN is required for AML cell expansion in vivo To determine the role of JUN in leukemia growth ex vivo and in vivo, the genetically engineered mouse model of AML driven by MLL-AF9 was employed. 36 Specifically, MLL-AF9 leukemia cells recovered from leukemic mice were engineered to co-express GFP in combination with either shNT or shRNAs that target murine Jun expression. Subsequently, cells from each condition were purified by fluorescence-activated cell sorting and assessed for protein expression and colony-forming capacity in methylcellulose (Supplementary Figure 2A) . Efficient depletion of JUN (Figure 1e ) significantly reduced the colony-forming capacity of MLL-AF9 leukemia cells (Figure 1f) .
To examine whether suppression of JUN impairs leukemia cell expansion in vivo, purified MLL-AF9 leukemia cells expressing either shNT or shJun-2 were transplanted separately into sublethally irradiated syngeneic mice (Supplementary Figure 2A) . Recipient mice transplanted with shJun-2-expressing leukemia cells displayed a significantly longer disease latency (P = 0.0003) than recipients transplanted with shNT-expressing leukemia cells ( Figure 1g ). As an additional assessment of how JUN inhibition influences AML growth in vivo, a competitive leukemia assay was performed (Supplementary Figure 2A) . Specifically, primary MLL-AF9 leukemia cells were separately transduced with recombinant lentiviruses that co-express GFP and shNT, shJun-1 or shJun-2 at an multiplicity of infection of 0.5. Heterogeneous mixtures of GFP-(untransduced) and GFP+ (transduced) cells from each shRNA condition were then separately transplanted into sublethally irradiated syngeneic recipient mice. Twenty-five days after transplant, all recipient mice from each condition developed frank leukemia with similar disease burdens, characterized by splenomegaly and neutrophilia (Supplementary Figures 2B and C, respectively). Flow cytometric analysis of several hematopoietic organs showed that mice transplanted with MLL-AF9 leukemia cells expressing either shJun-1 or shJun-2 displayed significantly lower percentages of GFP+ cells in the peripheral blood (P = 0.0069 and P = 0.0059) and spleen (P = 0.0344 and P = 0.0318) compared with mice transplanted with control (shNT expressing) MLL-AF9 leukemia cells (Supplementary Figure 1D) . The percentage of GFP+ cells in the bone marrow (BM) of mice transplanted with shJun-1 cells was also significantly lower (P = 0.043) than mice transplanted with shNT-expressing cells (Supplementary Figure 1D) . Although not significant, recipient mice transplanted with shJun-2-expressing MLL-AF9 leukemia cells displayed lower percentages of GFP+ cells in the BM compared with the BM of mice transplanted with shNTexpressing cells (Supplementary Figure 1D) .
To ensure that the anti-leukemia effects of JUN inhibition in vivo were not restricted to mouse or MLL-AF9-driven AML, U937 cells were transduced with shNT, shJUN-1 or shJUN-2 and subsequently transplanted into NSG mice (Supplementary Figures 3A-C) . Recipient mice transplanted with U937 cells expressing either shJUN-1 or shJUN-2 displayed significantly longer latency (P = 0.0014, shNT vs shJUN-1 and P = 0.0014, shNT vs shJUN-2) than recipient mice transplanted with shNT-expressing U937 cells (Supplementary Figure 3D) . Collectively, these observations suggest that JUN is a critical regulator of AML in vitro and in vivo. Figure 4A) . In addition, 2588 transcripts were decreased and 1083 transcripts were increased in shJUN-2-expressing THP-1 cells compared with shNT-THP-1 cells and a 495% overlap with shJUN-1 (Supplementary Figure 4A ).
JUN inhibition alters UPR transcriptional output
To identify molecular pathways that are influenced by JUN inhibition, a gene set/pathway enrichment analysis was performed using gene sets from the Molecular Signatures Database. 37 Using a Fisher's exact test (P o0.01), 656 gene sets were significantly altered by JUN inhibition. Organization of these results into a pathway enrichment map revealed that JUN knockdown altered several cellular processes including DNA replication, inflammatory responses, cell cycle regulation, immune processing and regulation as well as transcription factors involved in cancer (Supplementary Figure 4B) consistent with previous published studies. 3, 4, [38] [39] [40] Interestingly, gene sets annotated from human B cells experiencing ER stress 41 were also significantly enriched in shJUN-expressing THP-1 cells compared with shNT controls (Figure 2a) . Follow-up analysis found that a gene set annotated from promoters bound by the UPR transcriptional effectors ATF4 and CHOP 42 was also significantly enriched-more so than any of the curated pathways examined-in THP-1 cells expressing either shJUN compared with shNT controls (Supplementary Figure 4C , shJUN-1, P = 2.44 × 10 − 22 and shJUN-2, P = 3.98 × 10 − 19 ), indicating that JUN may regulate UPR-related transcriptional programs.
JUN binds to the promoters of UPR target genes Numerous UPR-regulated genes were significantly altered by JUN inhibition including the UPR transcriptional effectors ATF4 and XBP1 (Figure 2a) . Quantitative real-time PCR analysis confirmed that shRNA-mediated inhibition of JUN resulted in decreased Retrospective analysis of chromatin immunoprecipitation sequencing data deposited on the University of California Santa Cruz browser [43] [44] [45] showed that, in several human cell lines with distinct developmental origins, JUN binding is enriched at positions +1.3, − 0.3 and − 0.25 kb relative to the transcription start site of the XBP1, ATF4 and CHOP promoters, respectively (Supplementary Figure 5B) . Chromatin immunoprecipitation assays carried out on THP-1 cells using JUN and control IgG antibodies revealed that JUN binding is enriched at the transcription start site of the JUN promoter (Figure 2c , first panel), consistent with its reported ability to regulate its own expression. 3, 4 It was also observed that JUN also binds to the +1.3, − 0.3 and − 0.25 kb sites of the XBP1, ATF4 and CHOP promoters, respectively, in THP-1 cells (Figure 2c; Supplementary Figure 5C ). Collectively, these results suggest that JUN binds to the ATF4, XBP1s and CHOP promoter regions to drive their transcription.
JUN maintains basal protein levels of XBP1s and ATF4
To assess the impact of JUN inhibition on protein levels of XBP1s and ATF4, western blot analyses performed on lysates from several human AML cell lines expressing shNT, shJUN-1 or shJUN-2. JUN inhibition resulted in decreased protein expression of both ATF4 and XBP1s in THP-1, MOLM14, SKM1 and U937 cells (Figure 2d; Supplementary Figure 6 ). Depletion of JUN resulted in decreased expression of ATF4 and XBP1s, but did not have an impact on the expression or phosphorylation of their UPR upstream sensors, PERK and IRE1α, respectively (Figure 2d ; Supplementary Figures 6A and B) . JUN inhibition in NOMO1 cells resulted in reduced levels of nuclear ATF6f (Supplementary Figure 6C) ; however, ATF6f was not detectable in U937 or THP-1 cells (data not shown). Although JUN depletion reduced CHOP transcript levels, protein levels of CHOP increased in MOLM14-, U937-, NOMO1-and THP-1-expressing shJUN-1 or shJUN-2 compared with controls ( Supplementary Figures 6B and D) .
To confirm that JUN also regulates ATF4 and XBP1s expression in MLL-AF9-expressing mouse leukemia cells, shNT-, shJun-1-or shJun-2-expressing MLL-AF9 leukemia cells were isolated by fluorescence-activated cell sorting and then subjected to western blot analysis (Supplementary Figure 7A) . Inhibition of JUN in mouse MLL-AF9 leukemia cells also resulted in decreased expression of ATF4 and XBP1s (Supplementary Figure 7B) . To assess whether increasing JUN levels would yield a concomitant increase in ATF4 and XBP1s expression, MLL-AF9 leukemia cells were infected with recombinant retroviruses expressing GFP alone (MIEG) or in combination with human JUN (MIEG-JUN; Supplementary Figure 7A) . Western blot analysis showed that increased expression of JUN leads to increased expression of ATF4 and XBP1s (Supplementary Figure 7C) . Collectively, these observations indicate that JUN positively regulates the expression of ATF4 and XBP1s in human and mouse AML cells.
The expression of JUN and UPR target genes correlates in multiple genetic subtypes of AML Given that JUN expression is indicative of JUN transcriptional activity 3, 4 and that JUN expression is increased in certain subtypes of AML such as inv (16) Figure 8) . Correlations between JUN and XBP1 were among the weakest; however, this could be the result of XBP1 being largely regulated post-transcriptionally. Using data extracted from the AML TCGA 2 data set, similar correlations between JUN and each of these six genes were observed in cytogenetically normal and complex karotype subtypes of AML (Supplementary Table 1 ). Collectively, these data show that JUN correlates with UPR signaling activity in AML patient-derived cells.
JUN expression increases in cells experiencing ER stress
To assess whether JUN expression is altered in cells experiencing ER stress, THP-1 cells were treated with vehicle, Thapsigargin (TG) or Tunicamycin A (TunA) for various times and then subjected to protein and mRNA analyses. As expected, TG or TunA treatment led to a gradual increase in the mRNA and protein levels of XBP1, ATF4, CHOP and GRP78. In THP-1 cells, JUN protein levels began to increase at 30-45 min post TG and TunA treatment and then continued to gradually increase up to 4 h post treatment (Figure 3a; Supplementary Figures 9B and C) . JUN mRNA levels began to increase at 30 min post TG or TunA treatment, maxing out at 90 min and then steadily declining from 90 to 240 min (Figure 3b; Supplementary Figure 9D) . To determine whether ERstress-induced JUN expression is conserved in human and mouse AML cells, MLL-AF9-expressing murine AML cells recovered from leukemia mice were treated with TG and assessed for changes in UPR signaling and transcriptional output at various time points post treatment (Supplementary Figure 10A) . Analysis of protein lysates showed that JUN, ATF4 and XBP1s protein levels were all increased by 45 min of TG treatment, whereas CHOP and GRP78 induction required 90 and 120 min, respectively (Supplementary Figure 10B) . Similar to human cells, JUN transcripts began to increase by 30 min of treatment, peaked at 120 min and then eventually declined after 4 h of TG treatment (Supplementary Figure 10C) , confirming that JUN is activated in response to ER stress in both human and mouse AML. precede the increase in JUN protein levels; however, both decline rapidly as JUN protein levels continue to increase (Figure 3a) . Given that JNK phosphorylation of JUN S73 promotes stabilization and activation of JUN, the impact of JNK inhibition on JUN S73 phosphorylation and JUN protein levels following ER stress was evaluated. Though the JNK inhibitor, SP600125 50 partially blocked JUN S73 phosphorylation, it was unable to blunt the increase in JUN protein following TG treatment (Figure 3c ). To ensure that these observations are not due to the pleiotropic effects of SP600125, total and phosphorylated levels of JUN in response to ER stress were also examined upon shRNA-mediated inhibition of JNK1 or JNK2. Similar to SP600125 treatment, neither shRNA-mediated inhibition of JNK1 nor JNK2 inhibition obstructed TG-mediated stabilization of JUN ( Supplementary Figures 11A and B) .
Alternatively, administration of U0126-a MEK inhibitor that effectively blocks the phosphorylation and activation of ERK1/2 (p-ERK1/2 T202/Y204 )-obstructed the induction of JUN protein levels, p-JUN S73 and p-JNK T183/Y185 following TG treatment (Figure 3c ), suggesting that MEK signaling, possibly through ERK, regulates the activation of JUN in response to ER stress.
JUN inhibition disrupts UPR signaling in response to ER stress
To evaluate whether JUN depletion impairs the activation of the UPR following acute pharmacological induction of ER stress, AML cell lines expressing shNT, shJUN-1 or shJUN-2 were treated with TG or TunA and subsequently analyzed for changes in the mRNA and protein expression of key UPR signaling components. Diminished JUN expression in vehicle-treated THP-1, U937 or NOMO1 cells resulted in significantly reduced basal mRNA levels of XBP1, CHOP, GRP78, GRP94 and ATF4 (except for U937 cells; Figure 4a ; Supplementary Figure 12A ). The expression of XBP1, CHOP, GRP78, GRP94 and ATF4 was also significantly reduced at 30 and 60 min following TG treatment in shJUN-1-and shJUN-2-expressing cells compared with similarly treated shNT cells (Figure 4a; Supplementary Figures 12A) . In addition, it was observed that JUN depletion obstructed the induction of ATF4 and XBP1s protein expression in several human AML cell lines treated with TG or TunA (Figure 4b; Supplementary Figure 12B) , indicating that JUN inhibition consistently alters UPR signaling in human AML cells exposed to ER stress.
ER stress exacerbates AML cell death induced by JUN depletion To assess whether AML cells depleted of JUN are more sensitive to ER stress, AML cells expressing shNT, shJUN-1 or shJUN-2 were challenged with either TG or TunA at a time after efficient JUN depletion but before maximal cell death. The combination of JUN depletion and either TunA or TG resulted in a significant increase in the percentage of Annexin V+, PI − cells compared with JUN depletion, TunA or TG treatment alone (Figure 4c ; Supplementary Figure 12C) . The observed increase in the percentage of Annexin V+/PI − cells in TunA-or TG-treated JUN-depleted cells was made 24 h post treatment. However, at longer times post stress, the increase in cell death mediated by JUN inhibition alone became so high that the amount of cell death between vehicleand ER-stress-interrogated JUN-depleted cells was nearly indistinguishable (data not shown).
Based on the observations that U0126 blocks JUN induction (Figure 3c ) and JUN inhibition sensitizes AML cells to TG (Figure 4c ; Supplementary Figure 12C) , the effects of U0126 and TG treatment on AML cell survival were assessed. Similar to JUN inhibition, U0126 enhanced cell death mediated by moderately lethal levels of TG (Supplementary Figure 12D) . Collectively, these data suggest that JUN depletion acutely sensitizes AML cells to ERstress-induced death.
JUN-regulated UPR signaling is activated by conventional AML chemotherapies The UPR signaling pathway has been implicated in chemotherapy activity and resistance in several solid tumor settings. 11 To examine how JUN and UPR components respond to chemotherapy treatment in AML, THP-1 cells were treated with a combination of 100 nM cytarabine (Ara-C) and 40 nM doxorubicin (Doxo), and subsequently assessed for changes in the expression of JUN and other UPR components over time. Similar to AML cells treated with TG or TunA, JUN expression increased at 60 min post Ara-C/Doxo treatment followed by increased XBP1s and ATF4 expression at 120 and 240 min, respectively (Supplementary Figure 13A) . Also analogous to TG-or TunA-treated AML cells, inhibition of JUN nullified the increases in XBP1s and ATF4 levels in response to increasing concentrations of Ara-C/Doxo (Supplementary Figure 13B) , raising the possibility that JUN and UPR may have a role in chemotherapy efficacy.
XBP1 or ATF4 inhibition induces AML cell apoptosis
To assess the respective functional roles of ATF4 and XBP1 in mediating the effects of JUN depletion on AML cell survival, THP-1 and U937 cells were engineered to express shRNAs targeting either ATF4 or XBP1 (Figure 5a; Supplementary Figure 14A ). Similar to JUN depletion, shRNA-mediated inhibition of either XBP1 or ATF4 resulted in increased caspase-3 cleavage (Figure 5a ) and the number of Annexin V+ cells compared with shNT controls (Figure 5b; Supplementary Figure 14B ). Also consistent with JUN inhibition, shRNA-mediated inhibition of either ATF4 or XBP1 sensitized THP-1 and U937 cells to AML cells to TG or TunA treatment (Supplementary Figures 15A and B, respectively) . Collectively, these results indicate that XBP1 or ATF4 are needed to support AML cell survival.
Inhibition of XBP1s or ATF4 blocks leukemia expansion in vivo
To evaluate the roles of XBP1 and ATF4 expression in AML growth ex vivo and in vivo, MLL-AF9 leukemia cells were engineered to co-express GFP and shRNAs that efficiently reduce either XBP1s or ATF4 murine expression. Transduced cells were then subjected to fluorescence-activated cell sorting to isolate GFP+ cells, which were then assessed for target protein knockdown, colony formation and AML induction in syngeneic recipients (Supplementary Figure 14C) . Efficient depletion of either XBP1s or ATF4 (Figure 5c ) significantly reduced the colony-forming abilities of MLL-AF9 leukemia cells in methylcellulose (Figure 5d ). Syngeneic recipient mice transplanted with fluorescence-activated cell sorting-purified cells expressing shATF-2-the more efficient shRNA at reducing ATF4 protein expression-displayed a significantly longer time of disease onset (P = 0.0006) compared with recipient mice transplanted with shNT-expressing cells (Figure 5e ). Depletion of XBP1s expression also significantly delayed disease onset (P40.0001) compared with shNT control mice (Figure 5e ). Collectively, these observations indicate that suppressing XBP1s or ATF4 expression in this genetically engineered mouse model of AML reduces the ability of leukemia cells to propagate in vivo and suggest that XBP1s and ATF4 are key effectors of the pro-leukemia function of JUN.
DISCUSSION
Here we have identified that the transcription factor JUN, which is elevated in various genetic subtypes of human AML, 5-9 supports AML cell growth and survival. We also demonstrate that JUN positively regulates basal and ER stress transcriptional output of the UPR in AML. Moreover, we have found that AML cells also require the UPR transcriptional effectors, XBP1 and ATF4 to maintain AML cell survival and expansion both in vitro and in vivo.
We have also observed that JUN expression positively correlates with the expression of the UPR target genes ATF3, ATF4, CHOP, HSPA5, PPP1R15B and XBP1 in several genetic subtypes of AML. However, the varying correlations between JUN and UPR target gene expression among AML subtype and UPR target gene suggest that the contribution of JUN to UPR signaling may be AML subtype specific. In 11q23 AMLs, we have found that JUN strongly correlates with UPR target gene expression, and that inhibition of JUN diminishes UPR signaling in AML cells expressing MLL-AF9-the product of the 11q23 translocation t(9;11)-indicating that JUN is a prime regulator of UPR signaling in this AML subtype. In some AML subtypes, such as t (15;17) , where correlations between JUN and UPR signaling are weak, it is possible that UPR signaling is regulated by JUN-independent factors in addition to or in replacement of JUN.
It has been proposed that UPR activation proceeds in a timeordered set of responses, where the initial stages aim to restore ER homeostasis by first shutting down protein synthesis and then engaging damage correcting transcriptional programs, whereas the latter steps function to transition cells towards apoptosis when ER stress persists or the accompanying damage is irreparable. 13 Collectively, our data suggest that JUN contributes to the pro-survival, corrective functions of the UPR in AML cells. First, JUN levels increase shortly after chemical induction of ER stress in parallel with the expression of XBP1s and ATF4 but before the induction of GRP78 and the pro-death transcription factor CHOP. Second, JUN regulates the expression of XBP1 and ATF4, both of which engage transcriptional programs aimed at restoring ER homeostasis. Third, inhibition of JUN leads to widespread AML cell apoptosis, which can be phenocopied by either XBP1 or ATF4 inhibition. Fourth, although inhibition of JUN resulted in decreased transcription of CHOP, we did observe that CHOP protein levels increase in several AML cell lines following JUN inhibition. This is consistent with previous studies that have shown that perturbations in pro-survival UPR signaling or non-conventional ER stresses result in increased translation of CHOP and subsequent apoptosis. 51, 52 Such mechanisms could potentially contribute to the pro-apoptotic effects of JUN inhibition. Fifth, chemical ER stressors, such as TG or TunA accelerate AML cell death mediated by JUN, ATF4 or XBP1 inhibition.
JUN is purported to be primarily regulated by two upstream kinase-mediated pathways, JNK and ERK. 47, 48 JNK activates JUN in response to stresses such as ultraviolet irradiation or inflammation, whereas ERK activates JUN in response to growth factor stimulation. 53 JNK is a well-established target of IRE1α and promotes both survival and death in response to ER stress. 54 In response to chemically induced ER stress, we have observed that JUN is phosphorylated at Ser73, which is a known substrate of JNK. 47, 48 However, we have also observed that pharmacological inhibition of MEK signaling-upstream activators of ERK1/2-blocks ER-stress-induced activation of JUN, whereas a chemical inhibitor of JNK does not. In addition, shRNA-mediated inhibition of JNK1 or JNK2 does not obstruct ER-stress-mediated stabilization of JUN. However, JNK1 and JNK2 are able to compensate for the loss of one another, and although U0126 effectively blocked TGmediated activation of ERK1/2 and JUN, it also blocked the activating phosphorylation events on JNK as well as p-JUN Ser73 . Collectively, these results suggest that ERK1/2 kinases are the primary activators of JUN in response to ER stress, but they do not completely eliminate the possibility that JNK signaling may have a role in ER-stress-induced activation of JUN.
The observation that JUN promotes the transcription of key UPR components in AML cells was previously unrecognized. Although previous studies have implicated roles for JUN in regulating ER stress responses, no consistent picture of whether JUN influences ER stress responses has emerged. For example, in murine fibroblasts, JUN inhibition protects cells from lethal doses of the ER stressor TG, 55 whereas, in contrast, deletion of JUN in murine hepatocytes results in sustained UPR signaling and subsequent cell damage and death. 56 In the hepatoma cell line Huh-7, JUN cooperates with CHOP to induce cell death in response to ER stress, 57 however, CHOP has also been described to suppress JUN expression to induce apoptosis in response to chronic ER stress. 58 Collectively, our data show that JUN positively regulates the UPR signal transduction network to promote AML cell survival. JUN is a basic leucine zipper (bZIP)-containing transcription factor that regulates the transcription of numerous genes by forming heterodimers with other bZIP-containing transcription factors. 3, 4 Moreover, the promoter selectivity of JUN is often dictated by its dimerization partner. Interestingly, ATF4 and XBP1s are also bZIPcontaining proteins raising the possibility they may influence the ability of JUN to regulate UPR transcriptional output. Though future studies will be needed to address this postulate, studies have shown that JUN binds to ATF4 to regulate certain transcriptional programs. 59, 60 The UPR possesses both pro-survival and pro-death capabilities and therefore it is not surprising that the UPR has both tumorpromoting and -suppressive effects in human cancer. 11 The bifurcated impact of the UPR on cell fate insinuates that therapeutically targeting components of this network requires a thorough understanding of the precise events that dictate whether the UPR promotes cell survival or death. The results here describe a previously unrecognized role of JUN as a key UPR regulator thus providing new insights into the roles of both JUN and the UPR in AML. They also suggest that targeting JUN, possibly resulting in the blockage of UPR signaling, will have therapeutic benefit in AML. Despite immense efforts, very few JUN-targeting small molecules have entered early clinical trials and the results of most have failed or remain unknown. Therefore, additional insights of how JUN and the UPR are regulated will be central to developing highly effective therapies that capitalize on the targeting potential of these pathways in AML and possibly other human cancers.
